CDK4 and breast carcinoma: Seventy per cent of all breast cancer cases are oestrogen receptor positive (ER+) and targeted therapies such as endocrine therapy or Cdk4/6 inhibitors are used to treat this clinical subtype, resulting in dramatic improvements in long-term survival rates.